When Brooks Nader stepped onto the cover of Maxim this September, the 28-year-old model looked every bit the confident star — silk slip, smoky gaze, and a body honed for glossy perfection. But behind the scenes, her preparation wasn’t just hours at the gym. It involved quietly adjusting her use of GLP-1 weight loss drugs, a move that has now thrust her into the center of a larger debate about beauty, health, and the microdosing trend sweeping the industry.
A Confession on Reality TV
On her Freeform reality series Love Thy Nader, the Sports Illustrated Swimsuit alum admitted she “upped” her GLP-1 dose ahead of the high-profile shoot. Normally, she said, she “microdoses” semaglutide — taking amounts below standard medical recommendations. “Since I have Maxim coming up and I’m probably gonna be half naked, I’m upping my dose a little because I want to be extra-snatched,” she confessed.
The cameras, however, caught more than a slim silhouette. Days before the shoot, Nader appeared faint in Zumba, nearly collapsed in a bathtub, and vomited on camera. Her sisters later confronted her after discovering multiple vials of semaglutide in their New York City fridge, raising concerns about sourcing and safety.
“Everyone in Modeling Is on It”
Despite the pushback, Nader brushed it off, telling viewers, “Taking these weight loss drugs in the modeling industry is so common. I probably know more models that are on it than aren’t.” That admission underscores how GLP-1s, originally designed for diabetes, have become ubiquitous in Hollywood and fashion circles.
The Rise of Microdosing
Microdosing — a term once associated with psychedelics — refers to taking a fraction of a recommended dose. For GLP-1 drugs like Ozempic or Wegovy, typical regimens start at 0.25 mg and climb to as high as 2.4 mg. But microdosers often take even less: as little as 0.05 mg per week, depending on compounded formulas not regulated by the FDA.
Dr. Melanie Jay, an obesity researcher at NYU Langone, explains that lower doses can help those sensitive to side effects or looking to cut costs on notoriously expensive prescriptions. “But generally, we do not get much weight loss with microdosing,” she cautions. The approach may work for those who are leaner to begin with — like Nader — but lacks research-backed evidence.
The Dangers and the Unknowns
Nader’s scattered vials and syringes highlight the risks of unsupervised dosing. Experts warn that compounded versions of GLP-1s leave room for error, contamination, and misuse. Beyond logistics, doctors are concerned about nutrition. Appetite suppression, while cosmetically appealing, can lead to skipped meals and deficiencies. Nader herself admitted to surviving on bone broth the day before her shoot.
“The cosmetic use case and everyone trying to capitalize on it is leading to the Wild West,” Jay says. “That raises a lot of safety concerns.”
The Real Cost of “Snatched”
For Nader, the regimen is not without sacrifice. “I’ve lost relationships, I’ve been taking these weight loss drugs. I haven’t been sleeping, I haven’t been eating. That’s been the cost and the price that I’ve had to pay,” she revealed.
Her candor has sparked debate: Is she shining a light on an unspoken industry norm, or normalizing a dangerous off-label trend? Either way, her confession illustrates how GLP-1s have shifted from a medical breakthrough to a cultural lightning rod — blurring lines between health, beauty, and risk in the age of extreme body management.
